NRx Pharmaceuticals, a clinical-stage biopharmaceutical company, announced that its wholly owned subsidiary HOPE Therapeutics Inc. has completed the acquisition of Dura Medical, a revenue-generating provider of interventional psychiatry services in Naples and Ft. Myers, Florida. Founded in 2018, Dura Medical specializes in treatments for depression, PTSD, suicidality, anxiety, and chronic pain through various therapies including Ketamine Infusion Therapy, Transcranial Magnetic Stimulation, Spravato(R), Stellate Ganglion Blocks, and traditional psychiatry.
The acquisition is part of HOPE Therapeutics' strategy to expand its network across Florida, with pending deals for Neurospa TMS and Cohen and Associates expected to bring the total to more than eight locations. This expansion enhances access to advanced mental health treatments in the region, addressing critical gaps in care for conditions that affect millions globally. Stephen Durand, Dura's founder and a U.S. Army veteran, has been appointed Director of Florida Clinic Operations, bringing valuable experience to the growing network.
NRx Pharmaceuticals focuses on developing therapeutics based on its NMDA platform for central nervous system disorders, including suicidal depression, chronic pain, and PTSD. The company's pipeline includes NRX-100, a preservative-free intravenous ketamine with Fast Track Designation for suicidal ideation in depression, and NRX-101, an oral D-cycloserine/lurasidone combination with Breakthrough Therapy Designation for suicidal bipolar depression. Recently, NRx filed an Abbreviated New Drug Application and initiated a New Drug Application for NRX-100, seeking the Commissioner's National Priority Voucher Program for suicidal depression treatment.
This acquisition underscores the growing integration of psychedelic and cannabis-adjacent therapies into mainstream healthcare, potentially setting a precedent for similar mergers and expanding treatment options for patients. For more details, refer to the full press release at https://ibn.fm/RSnyG. Additional updates on NRx Pharmaceuticals are available in the company's newsroom at https://ibn.fm/NRXP.
